Mimetogen Pharmaceuticals - Company & Market Research Reports

Mimetogen Pharmaceuticals is a biotechnology company that develops the use of peptidomimetics to treat ophthalmic diseases with high unmet medical needs. MIM-D3 is currently being evaluated in a multi-center Phase 3 clinical study in the United States for the treatment of dry eye syndrome. In addition, Mimetogen has developed novel therapeutic approaches or other ophthalmology indications, including glaucoma and other degenerative diseases of the retina. The company was founded in 2004 and is based in Montreal, Canada.


Back of the Eye Disorders: Novel Drugs and Delivery Technologies, 2017-2030 - Product Thumbnail Image

Back of the Eye Disorders: Novel Drugs and Delivery Technologies, 2017-2030

  • Report
  • 292 Pages
From
Artificial Tears - Global Strategic Analysis - Product Thumbnail Image

Artificial Tears - Global Strategic Analysis

  • Report
  • 221 Pages
From
Global Dry Eye Syndrome Drugs Market 2017-2021 - Product Thumbnail Image

Global Dry Eye Syndrome Drugs Market 2017-2021

  • Report
  • 88 Pages
From
Ocular Disorders: Rising Therapeutics, Technologies, and Devices - Overview  - Product Thumbnail Image

Ocular Disorders: Rising Therapeutics, Technologies, and Devices - Overview

  • Report
  • 208 Pages
From
Retinal Degeneration - Pipeline Insight, 2018 - Product Thumbnail Image

Retinal Degeneration - Pipeline Insight, 2018

  • Drug Pipelines
  • 217 Pages
From
Genetic Ophthalmology Disorders Drug Development Pipeline Review, 2017 - Product Thumbnail Image

Genetic Ophthalmology Disorders Drug Development Pipeline Review, 2017

  • Report
  • 138 Pages
From
  • 6 Results (Page 1 of 1)
Loading Indicator
adroll